Get to know and reach out to the experts at Profil.

Short Bio

Ulrike is a physician and has more than 12 years expertise in clinical research in diabetes with a background in clinical care for more than 9 years. At Profil she is appointed as a Scientific Study Advisor. Ulrike joined Profil in 2003. She has been Principle Investigator for several early clinical phase studies, in particular pharmacodynamic/ pharmacokinetic assessments executed with glucose clamp technique. 

Ulrike is an active member of the professional diabetes organisation EASD. She is a regular reviewer for Diabetes, Obesity and Metabolism. 

Publications

Here are Ulrikes's recent publications:

• Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026 Jul;28(7):5915-5925. doi: 10.1111/dom.70753. Epub 2026 Apr 22. PMID: 42017294; PMCID: PMC13243934. 
• Hövelmann U, Engberg S, Heise T, Kristensen NR, Nørgreen L, Zijlstra E, Ribel-Madsen R. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024 May;26(5):1941-1949. doi: 10.1111/dom.15510. Epub 2024 Feb 20. PMID: 38379002. 
• Heller S, Battelino T, Bailey TS, Pieber TR, Hövelmann U, Plum-Mörschel L, Melgaard AE, Aronson R, DiMeglio LA, Johansen T, Danne T. Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes Obes Metab. 2023 May;25(5):1351-1360. doi: 10.1111/dom.14987. Epub 2023 Feb 14. PMID: 36692230. 
• Plum-Mörschel L, Andersen LR, Hansen S, Hövelmann U, Krawietz P, Kristensen NR, Lehrskov LL, Haahr H. Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus. Clin Drug Investig. 2023 Feb;43(2):119-127. doi: 10.1007/s40261-022-01243-6. Epub 2023 Jan 11. PMID: 36631720; PMCID: PMC9902323. 
• Hövelmann U, Raiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. Diabetes Obes Metab. 2021 Dec;23(12):2670-2678. doi: 10.1111/dom.14519. Epub 2021 Aug 25. PMID: 34378861; PMCID: PMC9292719. 

• Hövelmann U, Reiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. DIABETES OBES METAB 2021 Aug 11. doi: 10.1111/dom.14519. Online ahead of print.

• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R. Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. 

• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J. Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print

• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study. DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print
• Hövelmann U, Braendholt Olsen M, Mouritzen U, Lamers D, Kronshage B, Heise T. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. DIABETES OBES METAB 2018 Oct 23. doi: 10.1111/dom.13562. (Epub ahead of print)
• Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Moller DV, Heise T.
  Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. DIABETES CARE 2017 Dec 22. doi: 10.2337/dc17-1402. (Epub ahead of print)
• Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas.
  CLIN DRUG INVEST 2017 Jun 8. doi: 10.1007/s40261-017-0539-7. (Epub ahead of print)
• Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KM, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions. CLIN DRUG INVESTIG 37: 503-509, 2017  
• Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. DIABETES OBES METAB 19: 482-488, 2017
• Heise T, Stender-Petersen K, Hövelmann U, Jacobsen JB, Nosek L, Zijlstra E, Haahr H.
  Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus.
  CLIN PHARMACOKINET 2016 Nov 22. doi: 10.1007/s40262-016-0473-5. (Epub ahead of print)
• Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. DRUGS AGING 34 (1): 29-38, 2017
• Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control. DIABETES CARE 39: 1486-1492, 2016
• Heise T, Hövelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
  EXPERT OPIN DRUG METAB TOXICOL 11: 1193-1201, 2015.
• Heise T, Hövelmann U, Brondsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. DIABETES OBES METAB 17: 682-688, 2015.

Browse Profil's list of publications to see our other publications.

Selected Achievements and Work Experience